Tratamiento médico de 44 pacientes con carcinoma del conducto anal. Intergrupo Argentino para el Tratamiento de los Tumores Gastro-Intestinales (IATTGI) / [Medical treatment of 44 patients with anal canal carcinoma. Argentinian Intergroup for the treatment of gastrointestinal tumors (IATTGI)]

In order to investigate the medical treatment of anal canal carcinoma (ACC), 27 patients (pts) were treated with cisplatin, fluorouracil and radiotherapy, in an alternating schedule. Eleven pts received mitomycin C, fluorouracil and radiotherapy, in a concurrent scheme. Finally, six pts were included in a new outpatient scheme with cisplatin, fluorouracil, leucovorin, mitomycin C and concurrent radiotherapy. Within the first schedule, 25 pts were evaluable and 18 achieved complete response. All of them are disease free until now. With the second scheme, 7/10 pts had a complete response and 5 of them are alive and disease free. All the pts included in the last schedule (6/6) achieved complete remission. There were no deaths related to toxicity. Our experience is one of the earliest in oncology using cisplatin as a first line drug, in the non-surgical treatment of ACC. We think that the use of cisplatin is feasible, its toxicity is manageable, and its effectivity is similar to other schedules, as observed in our last scheme.

5 flourouracilo en altas dosis: fundamentos y toxicidad / 5 fluorouracil in high doses: basis and toxicity

El 5 fluorouracilo es el quimioterápico fundamental en el tratamiento del cáncer digestivo. Para obtener un mejor índice terapéutico, se puede emplear este fármaco en altas dosis (3 gr./m2), asociado a allopurinol, que previene la toxicidad en tejidos normales. En este trabajo se evalúan fundamentalmente los efectos colaterales en 20 pacientes portadores de neplasias avanzadas. Se demuestra la aparición de efectos tóxicos en un nivel aceptable que permite el uso de esta forma de suministrar el fármaco mencionado